Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

Immune checkpoint blockers (ICB) provide a promising approach to antitumor immunotherapy through blockade of immunosuppressive pathways. The synthetic glycolipid, ABX196, is a potent stimulator of invariant natural killer T cells (iNKT), a small subset of regulatory lymphocytes, which are powerful e...

Descripción completa

Detalles Bibliográficos
Autores principales: Scherrer, Didier, Barrett, Noel, Teyton, Luc, Pearce, Tillman, Nitcheu, Josianne, Pouletty, Philippe, Santo, Julien, Ehrlich, Hartmut J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716246/
https://www.ncbi.nlm.nih.gov/pubmed/36198025
http://dx.doi.org/10.1158/1535-7163.MCT-22-0183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716246/
https://www.ncbi.nlm.nih.gov/pubmed/36198025
http://dx.doi.org/10.1158/1535-7163.MCT-22-0183

Ejemplares similares